Literature DB >> 1733066

Down-regulation of the immune response to histocompatibility antigens and prevention of sensitization by skin allografts by orally administered alloantigen.

M H Sayegh1, Z J Zhang, W W Hancock, C A Kwok, C B Carpenter, H L Weiner.   

Abstract

The effects of oral administration of major histocompatibility antigens on the alloimmune response have not been investigated. Lymphocytes from inbred LEW (RT1u) rats that were pre-fed allogeneic WF (RT1l) splenocytes exhibited significant antigen specific reduction of the mixed lymphocyte response in vitro and delayed-type hypersensitivity response in vivo, when compared with unfed controls. In an accelerated allograft rejection model, LEW rats were presensitized with BN (RT1n) skin allografts 7 days before challenging them with (LEW x BN)F1 or BN vascularized cardiac allografts. While sensitized control animals hyperacutely reject their cardiac allografts within 2 days, animals prefed with BN splenocytes maintained cardiac allograft survival to 7 days, a time similar to that observed in unsensitized control recipients. This phenomenon was antigen-specific, as third-party WF grafts were rejected within 2 days. Immunohistologic examination of cardiac allografts harvested on day 2 from the fed animals had markedly reduced deposition of IgG, IgM, C3, and fibrin. In addition, there were significantly fewer cellular infiltrates of total white blood cells, neutrophils, macrophages, T cells, IL-2 receptor-positive T cells, and mononuclear cells with positive staining for the activation cytokines IL-2 and IFN-g. On day 6 posttransplant, the grafts from fed animals showed immunohistologic changes typical of acute cellular rejection usually seen in unsensitized rejecting controls. Feeding allogeneic splenocytes prevents sensitization by skin grafts and transforms accelerated rejection of vascularized cardiac allografts to an acute form typical of unsensitized recipients. Oral administration of alloantigen provides a novel approach to down-regulate the specific systemic alloimmune response against histocompatibility antigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733066     DOI: 10.1097/00007890-199201000-00033

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

Review 1.  Allopeptides and the alloimmune response.

Authors:  Ankit Bharat; T Mohanakumar
Journal:  Cell Immunol       Date:  2007-07       Impact factor: 4.868

Review 2.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 3.  Oral tolerance in disease.

Authors:  P Garside; A M Mowat; A Khoruts
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 4.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

5.  Induction of specific transplantation immunity by oral immunization with allogeneic cells.

Authors:  V Holán; A Zajícová; M Krulová; J Plsková; J Fric; M Filipec
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

Review 6.  Antigen-specific therapies for the treatment of autoimmune diseases.

Authors:  D A Hafler; H L Weiner
Journal:  Springer Semin Immunopathol       Date:  1995

Review 7.  A review of the mechanisms of oral tolerance and immunotherapy.

Authors:  W Sosroseno
Journal:  J R Soc Med       Date:  1995-01       Impact factor: 5.344

Review 8.  Therapeutic advances in immunosuppression.

Authors:  A W Thomson; J V Forrester
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

9.  Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response.

Authors:  W W Hancock; S J Khoury; C B Carpenter; M H Sayegh
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

Review 10.  Oral tolerance.

Authors:  Henry Yim Wu; Howard L Weiner
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.